Όλο το DSpace

Πλοήγηση ανά Θέμα "beta thalassemia"

Αποτελέσματα 1-10 από 10

    • Aiming towards hepatitis C virus elimination in Greece 

      Papatheodoridis G.V., Goulis J., Sypsa V., Lionis C., Manolakopoulos S., Elefsiniotis I., Anagnostou O., Tsoulas C., Hatzakis A., Dalekos G.N. (2019)
      There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic National Plan for Hepatitis C was announced ...

    • Apolipoprotein E Polymorphism and Left Ventricular Failure in Beta-Thalassemia: A Multivariate Meta-Analysis 

      Dimou N.L., Pantavou K.G., Bagos P.G. (2017)
      Apolipoprotein E (ApoE) is potentially a genetic risk factor for the development of left ventricular failure (LVF), the main cause of death in beta-thalassemia homozygotes. In the present study, we synthesize the results ...

    • Development of a novel PTD-mediated IVT-mRNA delivery platform for potential protein replacement therapy of metabolic/genetic disorders 

      Miliotou A.N., Pappas I.S., Spyroulias G., Vlachaki E., Tsiftsoglou A.S., Vizirianakis I.S., Papadopoulou L.C. (2021)
      The potential clinical applications of the powerful in vitro-transcribed (IVT)-mRNAs, to restore defective protein functions, strongly depend on their successful intracellular delivery and transient translation through the ...

    • Fibroblast Growth Factor 23 (FGF23) and Klotho Protein in Beta-Thalassemia 

      Stefanopoulos D., Nasiri-Ansari N., Dontas I., Vryonidou A., Galanos A., Psaridi L., Fatouros I.G., Mastorakos G., Papavassiliou A.G., Kassi E., Tournis S. (2020)
      Derangements in phosphate and calcium homeostasis are common in patients with beta-thalassemia. Fibroblast growth factor 23 (FGF23) is among the main hormones regulating phosphate levels, while several studies underline ...

    • In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies 

      Li C., Georgakopoulou A., Newby G.A., Everette K.A., Nizamis E., Paschoudi K., Vlachaki E., Gil S., Anderson A.K., Koob T., Huang L., Wang H., Kiem H.-P., Liu D.R., Yannaki E., Lieber A. (2022)
      Individuals with β-thalassemia or sickle cell disease and hereditary persistence of fetal hemoglobin (HPFH) possessing 30% fetal hemoglobin (HbF) appear to be symptom free. Here, we used a nonintegrating HDAd5/35++ vector ...

    • Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? 

      Zachou K., Arvaniti P., Gatselis N.K., Azariadis K., Papadamou G., Rigopoulou E., Dalekos G.N. (2017)
      Background & objectives: In the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of ...

    • Restless legs syndrome/Willis–Ekbom disease prevalence in beta thalassemia patients 

      Dimitriadou E., Giannaki C.D., Tsekoura M., Stefanidis I., Hadjigeorgiou G.M., Lavdas E., Karatzaferi C., Sakkas G.K. (2018)
      Purpose: Both beta thalassemia and restless legs syndrome (RLS) patients share some common pathophysiological characteristics related to iron handling. In the present study, the aim was to explore the prevalence of RLS as ...

    • Susceptibility of β-thalassemia heterozygotes to COVID-19 

      Sotiriou S., Samara A.A., Vamvakopoulou D., Vamvakopoulos K.-O., Sidiropoulos A., Vamvakopoulos N., Janho M.B., Gourgoulianis K.I., Boutlas S. (2021)
      Background: β-Thalassemia is the most prevalent single gene blood disorder, while the assessment of its susceptibility to coronavirus disease 2019 (COVID-19) warrants it a pressing biomed-ical priority. Methods: We studied ...

    • Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease 

      Sinakos E., Kountouras D., Koskinas J., Zachou K., Karatapanis S., Triantos C., Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V. (2017)
      Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for ...

    • Vulnerability of β-Thalassemia Heterozygotes to COVID-19: Results from a Cohort Study 

      Sotiriou S., Samara A.A., Lachanas K.E., Vamvakopoulou D., Vamvakopoulos K.-O., Vamvakopoulos N., Janho M.B., Perivoliotis K., Donoudis C., Daponte A., Gourgoulianis K.I., Boutlas S. (2022)
      Background: The assignment of mortality risk from SARS-CoV-2 virus (COVID-19) to vulnerable patient groups is an important step toward containment of the pandemic. Methods: A total of 760 patients with a positive molecular ...